Literature DB >> 17434715

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.

Marie-Cécile Bralet1, Bruno Falissard, Xavier Neveu, Margaret Lucas-Ross, Anne-Marie Eskenazi, Richard S E Keefe.   

Abstract

Schizophrenic patients demonstrate impairments in several key dimensions of cognition. These impairments are correlated with important aspects of functional outcome. While assessment of these cognition disorders is increasingly becoming a part of clinical and research practice in schizophrenia, there is no standard and easily administered test battery. The BACS (Brief Assessment of Cognition in Schizophrenia) has been validated in English language [Keefe RSE, Golberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensibility, and comparison with a standard neurocognitive battery. Schizophr. Res 2004;68:283-97], and was found to be as sensitive to cognitive dysfunction as a standard battery of tests, with the advantage of requiring less than 35 min to complete. We developed a French adaptation of the BACS and this study tested its ease of administration and concurrent validity. Correlation analyses between the BACS (version A) and a standard battery were performed. A sample of 50 stable schizophrenic patients received the French Version A of the BACS in a first session, and in a second session a standard battery. All the patients completed each of the subtests of the French BACS . The mean duration of completion for the BACS French version was 36 min (S.D.=5.56). A correlation analysis between the BACS (version A) global score and the standard battery global score showed a significant result (r=0.81, p<0.0001). The correlation analysis between the BACS (version A) sub-scores and the standard battery sub-scores showed significant results for verbal memory, working memory, verbal fluency, attention and speed of information processing and executive functions (p<0.001) and for motor speed (p<0.05). The French Version of the BACS is easier to use in French schizophrenic patients compared to a standard battery (administration shorter and completion rate better) and its good psychometric properties suggest that the French Version of the BACS may be a useful tool for assessing cognition in schizophrenic patients with French as their primary language.

Entities:  

Mesh:

Year:  2007        PMID: 17434715     DOI: 10.1016/j.eurpsy.2007.02.001

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  9 in total

1.  Cognitive impairments in psychotic disorders: common mechanisms and measurement.

Authors:  Deanna M Barch; Julia M Sheffield
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

2.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

3.  Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.

Authors:  Julie Eve Desmarais; Linda Beauclair; Lawrence Annable; Marie-Claire Bélanger; Theodore T Kolivakis; Howard C Margolese
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

4.  Age-dependent discrepancies between computerized and paper cognitive testing in patients with schizophrenia.

Authors:  Sylvain Grignon; Claire-Anne Grégoire; Myriam Durand; Marie Mury; Dominique Elie; Jean Marc Chianetta
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-25       Impact factor: 4.328

5.  Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia.

Authors:  Taisuke Yoshida; Motomu Suga; Kunimasa Arima; Yasuko Muranaka; Tsunehiko Tanaka; Satoshi Eguchi; Crystal Lin; Sumiko Yoshida; Masanori Ishikawa; Yuko Higuchi; Tomonori Seo; Yoshinori Ueoka; Masahito Tomotake; Yasuhiro Kaneda; David Darby; Paul Maruff; Masaomi Iyo; Kiyoto Kasai; Teruhiko Higuchi; Tomiki Sumiyoshi; Tetsuro Ohmori; Kiyohisa Takahashi; Kenji Hashimoto
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

6.  Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).

Authors:  Geovany Eliberto Araújo; Camilo Brandão de Resende; Ana Cecília Alves Cardoso; Antonio Lúcio Teixeira; Richard S E Keefe; João Vinícius Salgado
Journal:  Clinics (Sao Paulo)       Date:  2015-04       Impact factor: 2.365

7.  Association of genetic variants at 22q11.2 chromosomal region with cognitive performance in Japanese patients with schizophrenia.

Authors:  Kazufumi Akiyama; Atsushi Saito; Satoshi Saito; Yuji Ozeki; Takashi Watanabe; Kumiko Fujii; Kazutaka Shimoda
Journal:  Schizophr Res Cogn       Date:  2019-03-26

8.  Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among chronic schizophrenic inpatients.

Authors:  Jean-Pierre Clément; Benjamin Calvet; Chadia Haddad; Pascale Salameh; Souheil Hallit; Sahar Obeid; Georges Haddad
Journal:  BMC Psychiatry       Date:  2021-05-01       Impact factor: 4.144

9.  Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia.

Authors:  Liang-Jen Wang; Pao-Yen Lin; Yu Lee; Yu-Chi Huang; Su-Ting Hsu; Chi-Fa Hung; Chih-Ken Chen; Yi-Chih Chen; Ya-Ling Wang; Ming-Che Tsai
Journal:  Neuropsychiatr Dis Treat       Date:  2016-10-31       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.